As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Study of Hepatitis C Virus Outcomes After Treatment in Patients with Bleeding Disorders

Clinical Trial Title: 
Hepatitis C virus (HCV) outcomes after treatment with direct acting agents (DAA) in patients with bleeding disorders.
Clinical Trial Protocol ID: 
17012404
Clinical Trial Investigator Name: 
Lisa Boggio, MD
Clinical Trial Protocol Description: 

Blood collection for HCV:

  • Six months after Baseline Visit
  • 1 year after Baseline
  • 18 Months after Baseline
  • 2 Years after Baseline
Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are a male or female with hemophilia or other bleeding disorder.
  • Are 25 years of age or older.
  • Have had exposure to any direct acting agents.
  • Have a diagnosis of HCV.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 942-3034
Contact Name: 
Lisa Boggio, MD